Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/71635
Full metadata record
DC FieldValueLanguage
dc.contributor.authorApichard Sukonthasarnen_US
dc.contributor.authorYook Chin Chiaen_US
dc.contributor.authorJi Guang Wangen_US
dc.contributor.authorJennifer Nailesen_US
dc.contributor.authorPeera Buranakitjaroenen_US
dc.contributor.authorHuynh Van Minhen_US
dc.contributor.authorNarsingh Vermaen_US
dc.contributor.authorSatoshi Hoshideen_US
dc.contributor.authorJinho Shinen_US
dc.contributor.authorYuda Turanaen_US
dc.contributor.authorJam Chin Tayen_US
dc.contributor.authorBoon Wee Teoen_US
dc.contributor.authorSaulat Siddiqueen_US
dc.contributor.authorJorge Sisonen_US
dc.contributor.authorYu Qing Zhangen_US
dc.contributor.authorTzung Dau Wangen_US
dc.contributor.authorChen Huan Chenen_US
dc.contributor.authorKazuomi Karioen_US
dc.date.accessioned2021-01-27T03:59:59Z-
dc.date.available2021-01-27T03:59:59Z-
dc.date.issued2020-01-01en_US
dc.identifier.issn17517176en_US
dc.identifier.issn15246175en_US
dc.identifier.other2-s2.0-85092900306en_US
dc.identifier.other10.1111/jch.14075en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85092900306&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/71635-
dc.description.abstract© 2020 Wiley Periodicals LLC Polypill is a fixed-dose combination of medications with proven benefits for the prevention of cardiovascular disease (CVD). Its role in CVD prevention has been extensively debated since the inception of this concept in 2003. There are two major kinds of polypills in clinical studies. The first is polypill that combines multiple low-dose medications for controlling only one CVD risk factor (such as high blood pressure or high serum cholesterol). These “single-purpose” polypills were mostly developed from original producers and have higher cost. The polypill that combines 3-4 pharmaceutical components, each with potential to reduce one major cardiovascular risk factors is “multi-purpose” or “cardiovascular” polypill. Using data from various clinical trials and from meta-analysis, Wald and Law claimed that this “cardiovascular” polypill when administered to every individual older than 55 years could reduce the incidence of CVD by more than 80%. Several short and intermediate to long-term studies with different cardiovascular polypills in phase II and III trials showed that they could provide better adherence, equivalent, or better risk factor control and quality of life among users as compared to usual care. One recently published randomized controlled clinical trial demonstrated the effectiveness and safety of a four-component polypill for both primary and secondary CVD prevention with acceptable number needed to treat (NNT) to prevent one major cardiovascular event. Considering the slow achievement of CVD prevention in many poor- and middle-income Asian countries and also the need to further improve compliance of antihypertensive and lipid lowering medications in many high-income Asian countries, the concept of “cardiovascular polypill” could be very useful. With further support from ongoing polypill cardiovascular outcome trials, polypill could be the foundation of the population-based strategies for CVD prevention.en_US
dc.subjectMedicineen_US
dc.titleThe feasibility of polypill for cardiovascular disease prevention in Asian Populationen_US
dc.typeJournalen_US
article.title.sourcetitleJournal of Clinical Hypertensionen_US
article.stream.affiliationsUniversity Medicine and Pharmacy, Hue Universityen_US
article.stream.affiliationsDe La Salle Medical and Health Sciences Instituteen_US
article.stream.affiliationsSunway Universityen_US
article.stream.affiliationsHanyang University Medical Centeren_US
article.stream.affiliationsJichi Medical Universityen_US
article.stream.affiliationsShanghai Jiao Tong University School of Medicineen_US
article.stream.affiliationsUniversity of the East Ramon Magsaysay Memorial Medical Centeren_US
article.stream.affiliationsUniversitas Katolik Indonesia Atma Jayaen_US
article.stream.affiliationsUniversity of Malayaen_US
article.stream.affiliationsFuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Collegeen_US
article.stream.affiliationsYong Loo Lin School of Medicineen_US
article.stream.affiliationsNational Taiwan University College of Medicineen_US
article.stream.affiliationsKing George's Medical Universityen_US
article.stream.affiliationsFaculty of Medicine, Siriraj Hospital, Mahidol Universityen_US
article.stream.affiliationsNational Yang-Ming University, School of Medicineen_US
article.stream.affiliationsTan Tock Seng Hospitalen_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsPunjab Medical Centeren_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.